Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design - Wikidata - thesis-toulmin - TriplyDB

Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design

Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design

http://www.wikidata.org/entity/Q27651402

about

Fragment screening and HIV therapeutics Discrimination between Closely Related Cellular Metabolites by the SAM-I Riboswitch Crystallographic Study of a Novel Subnanomolar Inhibitor Provides Insight on the Binding Interactions of Alkenyldiarylmethanes with Human Immunodeficiency Virus-1 Reverse Transcriptase Structure of HIV-1 Reverse Transcriptase with the Inhibitor β-Thujaplicinol Bound at the RNase H Active Site Crystal Structure of tert -Butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in Complex with HIV-1 Reverse Transcriptase (RT) Redefines the Elastic Limits of the Non-nucleoside Inhibitor-Binding Pocket Synthesis, Activity, and Structural Analysis of Novel α-Hydroxytropolone Inhibitors of Human Immunodeficiency Virus Reverse Transcriptase-Associated Ribonuclease H HIV-1 Reverse Transcriptase (RT) Polymorphism 172K Suppresses the Effect of Clinically Relevant Drug Resistance Mutations to Both Nucleoside and Non-nucleoside RT Inhibitors Crystal Structures of HIV-1 Reverse Transcriptase with Picomolar Inhibitors Reveal Key Interactions for Drug Design A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants Detecting Allosteric Sites of HIV-1 Reverse Transcriptase by X-ray Crystallographic Fragment Screening Snapshot of the equilibrium dynamics of a drug bound to HIV-1 reverse transcriptase Structural and Inhibition Studies of the RNase H Function of Xenotropic Murine Leukemia Virus-Related Virus Reverse Transcriptase HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism Protein–peptide complex crystallization: a case study on the ERK2 mitogen-activated protein kinase Extension into the entrance channel of HIV-1 reverse transcriptase—Crystallography and enhanced solubility Surface Reengineering of RPA70N Enables Cocrystallization with an Inhibitor of the Replication Protein A Interaction Motif of ATR Interacting Protein Structure-Based Evaluation of C5 Derivatives in the Catechol Diether Series Targeting HIV-1 Reverse Transcriptase Selective unfolding of one Ribonuclease H domain of HIV reverse transcriptase is linked to homodimer formation Structure of a Dihydroxycoumarin Active-Site Inhibitor in Complex with the RNase H Domain of HIV-1 Reverse Transcriptase and Structure–Activity Analysis of Inhibitor Analogs Structures of HIV-1 RT-RNA/DNA ternary complexes with dATP and nevirapine reveal conformational flexibility of RNA/DNA: insights into requirements for RNase H cleavage The "Sticky Patch" Model of Crystallization and Modification of Proteins for Enhanced Crystallizability.Application of protein engineering to enhance crystallizability and improve crystal properties.It's all in the crystals…4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants.Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase.Identification of mechanistically distinct inhibitors of HIV-1 reverse transcriptase through fragment screening.Differential isotopic enrichment to facilitate characterization of asymmetric multimeric proteins using hydrogen/deuterium exchange mass spectrometry.Advantages of crystallographic fragment screening: functional and mechanistic insights from a powerful platform for efficient drug discovery.Rapid experimental SAD phasing and hot-spot identification with halogenated fragments.Effect of translocation defective reverse transcriptase inhibitors on the activity of N348I, a connection subdomain drug resistant HIV-1 reverse transcriptase mutant.Examining the role of the HIV-1 reverse transcriptase p51 subunit in positioning and hydrolysis of RNA/DNA hybrids Design, Synthesis, and Biological Evaluations of Hydroxypyridonecarboxylic Acids as Inhibitors of HIV Reverse Transcriptase Associated RNase H.Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA.Solution characterization of [methyl-(13)C]methionine HIV-1 reverse transcriptase by NMR spectroscopy Mechanism of HIV antiretroviral drugs progress toward drug resistance.Structure of HIV-1 reverse transcriptase bound to a novel 38-mer hairpin template-primer DNA aptamer Insight into HIV-1 reverse transcriptase-aptamer interaction from molecular dynamics simulations.Will crystal parkin help in understanding the future of Parkinson's disease?Structural Insights into HIV Reverse Transcriptase Mutations Q151M and Q151M Complex That Confer Multinucleoside Drug Resistance.

P2860

Q26826945-6E88EEB5-246C-4E0D-B18D-10F3F3D07F36 Q27646576-FD33C675-C206-4C6D-99A0-CFF67E6A57F0 Q27657535-57A19AE3-5113-4CD2-B479-6592F4492A34 Q27658584-870B5B9E-5BB1-4C40-9DCA-051C3A043CE4 Q27667348-D09CD091-83AD-46BB-8393-0B5A4147346A Q27667836-6D753167-31B7-445B-9B21-DEF67BA5D885 Q27670634-D4453D87-021E-474B-9228-66CE7C9BFBF5 Q27675166-30064506-007D-43A4-BFFA-B1A313382318 Q27675380-D0BE47EC-4329-48A3-B659-A513EA44B1CF Q27675974-BA20C832-200F-43AD-A85F-6A6BC7A1657C Q27676461-5503FD2D-362B-46DD-B7C8-7D7A3E5486DC Q27676777-1647A2CA-E56F-4EC0-B2F5-22406717256C Q27676835-85B535B9-1F82-4CC5-8C63-15FBEE6959BB Q27676946-631990B6-F894-47FC-A34B-B8F9C8B23D12 Q27679282-51AB2A90-EF12-40F1-9878-15CC4F788576 Q27679772-648E05D0-F95A-4368-9CB1-296857865573 Q27680709-29BC5FC0-6BBA-4353-AC40-1BFCFC5BA9C8 Q27681926-14AC3452-98D8-4BED-A0BC-CF030D921E12 Q27683831-7E379FC0-7E0A-4B4F-892A-71DC92D0D4DE Q27684014-DC953BCB-476D-419F-AABD-C5F8509A7E12 Q30252224-E2BEE674-11AF-4E92-B925-188F9D3A087B Q30432379-4822A6B4-6F05-4E50-A48F-FC8374A4810D Q30432744-8F9CA13F-DC9D-4AB8-8B9C-0D8D9E822D92 Q34107343-71560F32-CA06-441C-A01B-96ED213026F7 Q35228851-9C9C5DCE-D946-489C-842D-3EEF6CD40E50 Q35633587-D70F29F0-8C26-4BD0-905E-A346F897AAB3 Q35650700-D215D4FB-8299-4075-A3B5-2CBD161A8F06 Q35654238-056B66A3-8454-4077-A426-64A0EA3AD69F Q35848043-0ABB112D-07CB-4B61-9D4D-5EA1456C279A Q36438686-0598C2D8-F3F8-41DB-97F0-7DE36EAF1F2E Q36553113-23A24B8B-57EC-434D-B0A0-84CB51B1E3E2 Q36890771-0949FDF0-FC62-4E9C-8DFE-981323EE303B Q36940608-003FAAD2-3E2B-4B99-9BFD-633A6C89BBC7 Q36964321-80441D6E-52C8-46E6-B4E7-A77D74654876 Q37252481-99A07264-E532-4BC8-8EAE-66A3A803DC1E Q37961181-FFF4B2FF-5C47-4B3B-864E-3038B9564B52 Q38296940-30451DA5-1F22-40A6-8E93-ED7282B3061A Q38305425-6C5F2F3D-F44E-4B67-B632-999FB676F439 Q39030585-C6898A94-CF48-47F4-BAC8-B485CF3AB62E Q40249141-4036F55E-F6CD-466D-87D8-441752B064F2

P2860

Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design

http://www.wikidata.org/entity/Q27651402

description

2008 nî lūn-bûn

@nan

2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design

@ast

Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design

@en

Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design

@nl

type

label

Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design

@ast

Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design

@en

Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design

@nl

prefLabel

Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design

@ast

Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design

@en

Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design

@nl

P1433

Q27651402-15703062-C591-4085-9848-F7D6FF23446F

P1476

Q27651402-ECBDB064-AB3B-4DE2-ADD3-A5EA7EACB035

P2093

Q27651402-06E45D37-F621-4BA6-A34E-AEE007C50B16

Q27651402-4B9F7819-3D0E-4447-B13F-86ED8BF804A2

Q27651402-6BFB122C-028F-46CD-9406-84E01F4D50E4

Q27651402-A3B0BA5B-BCC5-4A64-8285-86EDEB718681

Q27651402-C686F328-6587-4EBA-A5A2-9C734C70B076

Q27651402-C94992DB-4636-4ACB-BD80-13DFE5E6893F

Q27651402-E5E67E02-D68B-47C6-B02E-4BF1C05BDFAE

Q27651402-E7716B68-4C0E-4389-97D9-BB9119D080DB

Q27651402-EF994F27-8E86-47DA-9C01-EFC5AAAB3BDE

P2860

Q27651402-1C172A10-BCCD-4F68-8006-88F13F87E157

Q27651402-20989D0A-57E2-4F51-95CE-FB34D4E0EC15

Q27651402-3033E11E-29B2-4057-ABCA-D4D3318B586D

Q27651402-326834AF-3FD7-4273-BC82-DA9FE46A0A7A

Q27651402-37B2F0CA-4BCD-428E-920C-64C4B14DB9A2

Q27651402-37EFB104-ABF7-4D69-B1A5-E99C08FF0C36

Q27651402-4254EBA2-5BCC-4F5F-A50F-0F27BCCF0AFC

Q27651402-4E6787E4-4521-4E9E-B719-3443F364ED7A

Q27651402-6E09222B-6736-4C8F-B54A-F062A271504C

Q27651402-6EE7ADE4-61AA-4E62-8F21-C7F68308355D

P304

Q27651402-1D6FA24E-F10A-44E9-89AC-CBF7F279C63F

P31

Q27651402-411A73F9-0F8E-4BF4-B81F-0A8F839A7D45

P356

Q27651402-94C09746-EB10-4E26-89F1-6BF760807220

P407

Q27651402-5798AB46-CA68-4490-941F-5B600997B992

P433

Q27651402-E370655B-AD6B-4035-9133-90608AFFCD92

P478

Q27651402-7D3C2850-9111-4D9E-86DF-F4C754ED5521

P50

Q27651402-758B4800-0BCD-4E19-B3D6-085BEC0DCD18

Q27651402-C88B6D3D-06C2-4275-AC9F-A1EE3D4D5CF5

P577

Q27651402-8C2FA215-039F-4DE4-AD2A-F6E1B816E6A7

P5875

Q27651402-73C973E8-E31D-468C-A19C-0CA8C5B9594C

P698

Q27651402-232D72CA-8A0F-478D-868E-502E29E8D7D7

P932

Q27651402-C8FDC064-7093-49E9-881B-9B6C47AAA2E8

P356

P1433

Nucleic Acids Research

P1476

Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design

@en

P2093

Aaron J Shatkin

http://www.w3.org/2001/XMLSchema#string

Arthur D Clark

http://www.w3.org/2001/XMLSchema#string

Daniel M Himmel

http://www.w3.org/2001/XMLSchema#string

Deena A Oren

http://www.w3.org/2001/XMLSchema#string

Joseph D Bauman

http://www.w3.org/2001/XMLSchema#string

Kalyan Das

http://www.w3.org/2001/XMLSchema#string

Mukta Baweja

http://www.w3.org/2001/XMLSchema#string

Paul L Boyer

http://www.w3.org/2001/XMLSchema#string

William C Ho

http://www.w3.org/2001/XMLSchema#string

P2860

Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones

Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues

2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1

High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations.

The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1

High resolution structures of HIV-1 RT from four RT-inhibitor complexes

Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 A resolution

Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms

Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance

Site-directed mutagenesis by overlap extension using the polymerase chain reaction

P304

5083-92

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NAR/GKN464

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P50

Stephen H. Hughes

P577

2008-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23145767

http://www.w3.org/2001/XMLSchema#string

P698

18676450

http://www.w3.org/2001/XMLSchema#string

P932

2528191

http://www.w3.org/2001/XMLSchema#string